Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia (Q36691444)

15 August 2017

1 reference

title

Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia (English)

1 reference

15 August 2017

0 references

McTavish D

1

1 reference

15 August 2017

Sorkin EM

series ordinal

2

1 reference

15 August 2017

publication date

1 July 1991

1 reference

15 August 2017

1 reference

15 August 2017

volume

42

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

65-89

1 reference

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

15 August 2017

cites work

1 reference

12 December 2020

The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia

1 reference

12 December 2020

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

1 reference

12 December 2020

Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits

1 reference

12 December 2020

Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels

1 reference

12 December 2020

Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic

1 reference

12 December 2020

Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.

1 reference

12 December 2020

Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine

1 reference

12 December 2020

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

1 reference

12 December 2020

Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo

1 reference

12 December 2020

Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin

1 reference

12 December 2020

Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

1 reference

12 December 2020

Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)

1 reference

12 December 2020

Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia

1 reference

12 December 2020

Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test

1 reference

12 December 2020

The effect of pravastatin in relation to low density lipoprotein receptor activity

1 reference

12 December 2020

Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin.

1 reference

12 December 2020

Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia

1 reference

12 December 2020

Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects

1 reference

12 December 2020

Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.

1 reference

12 December 2020

Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia

1 reference

12 December 2020

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

1 reference

12 December 2020

Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine

1 reference

12 December 2020

Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I

1 reference

12 December 2020

The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects

1 reference

12 December 2020

Effect of CS-514 (pravastatin) on VLDL-triglyceride kinetics in rats.

1 reference

12 December 2020

Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth

1 reference

12 December 2020

Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: Lack of effect on low-density lipoprotein concentrations or turnover

1 reference

12 December 2020

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study

1 reference

12 December 2020

Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics

1 reference

12 December 2020

Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia

1 reference

12 December 2020

Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

1 reference

12 December 2020

Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens

1 reference

12 December 2020

Probucol versus eptastatin in hypercholesterolaemic diabetics

1 reference

12 December 2020

Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia

1 reference

12 December 2020

Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens

1 reference

12 December 2020

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing

1 reference

12 December 2020

Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study

1 reference

12 December 2020

Cholesterol metabolism in man

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin

1 reference

12 December 2020

Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia

1 reference

12 December 2020

The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers

1 reference

12 December 2020

[Effectiveness of pravastatin and bezafibrate in primary hypercholesterolemia]

1 reference

12 December 2020

Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects

1 reference

12 December 2020

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

1 reference

12 December 2020

10.2165/00003495-199142010-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1039961497

0 references

1 reference